Vi­tal Ther­a­pies evis­cer­at­ed as PhI­II dis­as­ter forces it to dis­card sole as­set

Vi­tal Ther­a­pies has built its whole op­er­a­tion up­on the cell-based treat­ment for acute liv­er fail­ure it calls ELAD. That foun­da­tion has now col­lapsed.

The San Diego-based biotech an­nounced that ELAD failed both pri­ma­ry and sec­ondary end­points in a Phase III tri­al, show­ing no sig­nif­i­cant im­prove­ment in over­all sur­vival or pro­por­tion of sur­vivors at study day 91 for pa­tients with se­vere al­co­holic he­pati­tis. See­ing no short path to ap­proval, Vi­tal has de­cid­ed to “cease any fur­ther de­vel­op­ment of the ELAD Sys­tem and ex­plore strate­gic op­tions.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.